Table 1. Open in new tab Predicitive...

Patients (N = 238)	AMH <1.2 ng/ml (n = 60)	Univariate analysis	Multivariate analysis
Patient characteristic	%
Age (y)	50.0 vs 22.3	1.9 (1.1–3.2)	0.03	1.9 (0.97–3.8)	0.06
≥35 vs <35
BMI (kg/m²)	25.0 vs 23.0	1.1 (0.6–2.2)	0.8	–	–
≥25 vs <25
Disease characteristic
NHL vs HL	22.8 vs 24.3	0.96 (0.7–1.4)	0.8	–	–
Adverse clinical symptoms, n = 228^a	26.1 vs 16.0	1.4 (0.95–1.9)	0.07	1.8 (1.1–2.9)	0.02
Yes vs No
Adverse biological parameters, n = 201^a	26.0 vs 6.3	2.3 (1.1–4.8)	0.01	2.5 (0.9–6.9)	0.03
Yes vs No
ECOG-PS score, n = 212^a	19.8 vs 32.0	1.4 (0.97–1.97)	0.07	1.1 (0.8–1.6)	0.67
0 vs ≥1
Lymphoma stage, n = 225^a Disseminated vs localized	31.8 vs 17.0	1.5 (1.1–2.1)	0.01	1.6 (1.1–2.3)	0.02

Patients (N = 238)	AMH <1.2 ng/ml (n = 60)	Univariate analysis	Multivariate analysis
Patient characteristic	%
Age (y)	50.0 vs 22.3	1.9 (1.1–3.2)	0.03	1.9 (0.97–3.8)	0.06
≥35 vs <35
BMI (kg/m²)	25.0 vs 23.0	1.1 (0.6–2.2)	0.8	–	–
≥25 vs <25
Disease characteristic
NHL vs HL	22.8 vs 24.3	0.96 (0.7–1.4)	0.8	–	–
Adverse clinical symptoms, n = 228^a	26.1 vs 16.0	1.4 (0.95–1.9)	0.07	1.8 (1.1–2.9)	0.02
Yes vs No
Adverse biological parameters, n = 201^a	26.0 vs 6.3	2.3 (1.1–4.8)	0.01	2.5 (0.9–6.9)	0.03
Yes vs No
ECOG-PS score, n = 212^a	19.8 vs 32.0	1.4 (0.97–1.97)	0.07	1.1 (0.8–1.6)	0.67
0 vs ≥1
Lymphoma stage, n = 225^a Disseminated vs localized	31.8 vs 17.0	1.5 (1.1–2.1)	0.01	1.6 (1.1–2.3)	0.02

Table 1.

Predicitive factors of AMH levels below 1.2 ng/ml before ovarian stimulation in patients with lymphoma (n = 238).

Patients (N = 238)	AMH <1.2 ng/ml (n = 60)	Univariate analysis		Multivariate analysis
		OR (95% CI)	P-value	OR (95% CI)	P-value
Patient characteristic	%
Age (y)	50.0 vs 22.3	1.9 (1.1–3.2)	0.03	1.9 (0.97–3.8)	0.06
≥35 vs <35	50.0 vs 22.3	1.9 (1.1–3.2)	0.03	1.9 (0.97–3.8)	0.06
BMI (kg/m²)	25.0 vs 23.0	1.1 (0.6–2.2)	0.8	–	–
≥25 vs <25	25.0 vs 23.0	1.1 (0.6–2.2)	0.8	–	–
Disease characteristic
NHL vs HL	22.8 vs 24.3	0.96 (0.7–1.4)	0.8	–	–
Adverse clinical symptoms, n = 228^a	26.1 vs 16.0	1.4 (0.95–1.9)	0.07	1.8 (1.1–2.9)	0.02
Yes vs No	26.1 vs 16.0	1.4 (0.95–1.9)	0.07	1.8 (1.1–2.9)	0.02
Adverse biological parameters, n = 201^a	26.0 vs 6.3	2.3 (1.1–4.8)	0.01	2.5 (0.9–6.9)	0.03
Yes vs No	26.0 vs 6.3	2.3 (1.1–4.8)	0.01	2.5 (0.9–6.9)	0.03
ECOG-PS score, n = 212^a	19.8 vs 32.0	1.4 (0.97–1.97)	0.07	1.1 (0.8–1.6)	0.67
0 vs ≥1	19.8 vs 32.0	1.4 (0.97–1.97)	0.07	1.1 (0.8–1.6)	0.67
Lymphoma stage, n = 225^a Disseminated vs localized	31.8 vs 17.0	1.5 (1.1–2.1)	0.01	1.6 (1.1–2.3)	0.02

Patients (N = 238)	AMH <1.2 ng/ml (n = 60)	Univariate analysis		Multivariate analysis
		OR (95% CI)	P-value	OR (95% CI)	P-value
Patient characteristic	%
Age (y)	50.0 vs 22.3	1.9 (1.1–3.2)	0.03	1.9 (0.97–3.8)	0.06
≥35 vs <35	50.0 vs 22.3	1.9 (1.1–3.2)	0.03	1.9 (0.97–3.8)	0.06
BMI (kg/m²)	25.0 vs 23.0	1.1 (0.6–2.2)	0.8	–	–
≥25 vs <25	25.0 vs 23.0	1.1 (0.6–2.2)	0.8	–	–
Disease characteristic
NHL vs HL	22.8 vs 24.3	0.96 (0.7–1.4)	0.8	–	–
Adverse clinical symptoms, n = 228^a	26.1 vs 16.0	1.4 (0.95–1.9)	0.07	1.8 (1.1–2.9)	0.02
Yes vs No	26.1 vs 16.0	1.4 (0.95–1.9)	0.07	1.8 (1.1–2.9)	0.02
Adverse biological parameters, n = 201^a	26.0 vs 6.3	2.3 (1.1–4.8)	0.01	2.5 (0.9–6.9)	0.03
Yes vs No	26.0 vs 6.3	2.3 (1.1–4.8)	0.01	2.5 (0.9–6.9)	0.03
ECOG-PS score, n = 212^a	19.8 vs 32.0	1.4 (0.97–1.97)	0.07	1.1 (0.8–1.6)	0.67
0 vs ≥1	19.8 vs 32.0	1.4 (0.97–1.97)	0.07	1.1 (0.8–1.6)	0.67
Lymphoma stage, n = 225^a Disseminated vs localized	31.8 vs 17.0	1.5 (1.1–2.1)	0.01	1.6 (1.1–2.3)	0.02

Multivariate analysis was performed after adjustments for age, adverse clinical symptoms, adverse biological parameters, ECOG PS, and lymphoma. Only variables which were significantly associated with AMH <1.2 ng/ml in univariate analysis were included in multivariate analysis.

AMH, anti-Müllerian hormone; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; OR, odds ratio.

No. of patients with available data.

This Feature Is Available To Subscribers Only